L’Oreal invests in Swiss biotech company, Timeline

L’Oreal invests in Swiss biotech company, Timeline

THE WHAT? L’Oreal’s venture capital fund, BOLD has acquired a minority stake in Timeline. The Swiss biotech company has developed a proprietary molecule that is said to recycle and rejuvenate aging mitochondria. Financial terms of the deal were not disclosed.

THE DETAILS “This strategic collaboration reflects the breakthrough multidimensional approach that we’ve always believed is necessary to make meaningful advancements for longevity and health span,” said Patrick Aebischer, Co-Founder and Chairman of Timeline. “I want to thank L’Oréal for its commitment to longevity solutions rooted in the highest level of science.”

THE WHY? The investment will enable Timeline to further develop its technology and expand operations while enabling future collaboration with L’Oreal.  

Barbara Lavernos, Deputy Chief Executive Officer and in charge of Research, Innovation and Technology, L’Oréal Groupe. “Longevity is about living healthier for longer and L’Oréal has been working for more than a decade to understand and anticipate what this could mean for beauty. Longevity adds a new dimension to beauty, focused on predicting, correcting and even reversing the ageing of our skin, scalp and hair. Our investment in Timeline is exciting for its potential to transpose key hallmarks of longevity onto skin health and beauty.”